Back to News & Events

Virtual SBIR/STTR Intensive Workshop – June 15 &16, 2021

Led by experts from BBC Entrepreneurial Training & Consulting, join our live Virtual Classroom for an interactive, 2 day SBIR/STTR workshop. We’ll review the basics including program purpose; eligibility; and sources of funding. Then we’ll provide proposal prep essentials of the NIH, NSF and DOE programs. In addition to up-to-date information on the SBIR/STTR programs, we will cover:

– NIH and NSF grant mechanisms and where to find them

– How to find the program officers, how to approach them, what questions to ask

– How to do research using the web tools available (eReporter, SBIR.gov, etc.)

– Common pitfalls and how to avoid them, and much more.

Workshop registration fee: $25.00. Please register online: https://cfbsbirtrain2021a.eventbrite.com

*Stony Brook University Faculty/Staff/Students may attend workshop at no cost – please contact Kate Hutchinson (kate.hutchinson@stonybrook.edu)  for details. 

Workshop is produced by the Center for Biotechnology at Stony Brook University and in partnership with Columbia Technology Ventures. The Center for Biotechnology also offers a follow on One-on-One Proposal Counseling program via a competitive application process. Learn more here: https://centerforbiotechnology.org/resources/programs/ 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3404 [post_author] => 3 [post_date] => 2020-01-02 16:35:15 [post_date_gmt] => 2020-01-02 16:35:15 [post_content] => ASPR/BARDA is issuing a Request for Information (RFI) to assist in understanding the developmental landscape of next generation blood products that could be used to treat mechanical trauma and bleeding associated with acute radiation syndrome and potentially supplement the blood supply in the wake of a mass casualty event such as a nuclear or radiological scenario. BARDA intends to use responses to this RFI for planning potential future acquisitions. BARDA seeks pertinent marketplace data to strengthen BARDA’s understanding of the current and future marketplace as well as enhance its ability to obtain quality services and products economically, and to efficiently and lawfully establish potential vendor source files and listings. BARDA will not award any potential contracts under this notice. This is strictly for market research. Link to the RFI: https://bit.ly/2LSjOEc . [post_title] => BARDA RFI: Next Generation Blood Products [post_excerpt] => ASPR/BARDA is issuing a Request for Information (RFI) to assist in understanding the developmental landscape of next generation blood products. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-rfi-next-generation-blood-products [to_ping] => [pinged] => [post_modified] => 2020-01-31 20:01:41 [post_modified_gmt] => 2020-01-31 20:01:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3404 [menu_order] => 81 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2621 [post_author] => 3 [post_date] => 2017-03-20 13:58:38 [post_date_gmt] => 2017-03-20 13:58:38 [post_content] => CEWIT, the Center for Biotechnology and Henry Schein, Inc., have joined forces to host an expert symposium presenting cutting-edge advances in biomedical and clinical-related technologies, digital health, and smart medical devices, focusing on the technology as well as the joint industry, academic, and R&D partnerships that are integral to major innovations in the healthtech domain — at Stony Brook University. Tuesday, March 28, 2017, 9:30am-3:30pm The Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University 1500 Stony Brook Road, Stony Brook, NY 11794-6040 Event is free but registration is requires. View full agenda and register here: www.cewit.org/events/healthtech.html [post_title] => CEWIT Medical Technologies and Healthcare Innovations Symposium [post_excerpt] => Featuring cutting-edge advances in biomedical and clinical-related technologies, digital health, and smart medical devices, focusing on the technology as well as the joint industry, academic, and R&D partnerships that are integral to major innovations in the healthtech domain — at Stony Brook University. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cewit-medical-technologies-and-healthcare-innovations-symposium [to_ping] => [pinged] => [post_modified] => 2017-03-20 13:59:29 [post_modified_gmt] => 2017-03-20 13:59:29 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2621 [menu_order] => 151 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3225 [post_author] => 3 [post_date] => 2019-04-05 19:35:45 [post_date_gmt] => 2019-04-05 19:35:45 [post_content] => Join the Center for Biotechnology for Roche Oncology Strategic Interests Presentation on Monday April 15, 2019. Fiona Mack, PhD, Director External Innovation, Pharmaceutical Research and Early Development for the Roche Innovation Center New York will be at Stony Brook University Medical Center to present Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. Fiona will also discuss Roche’s approach to investing in emerging novel therapeutics utilizing case studies as examples. April 15, 2019 10am-11am Radiation Oncology Conference Room (HOS L2-664) Stony Brook University Medical Center Level 2 Seating is limited. If you are interested in attending please contact Emily Kao at emily.kao@stonybrook.edu How to get to Stony Brook University Hospital Radiation Oncology Conference Room To access the Radiation Oncology Conference Room, please utilize the hospital main elevators and take down to Level 2. When you arrive on Level two proceed forward, following the signs to the "green elevators". You will find the Radiation Oncology conference room on your right hand side, room HOS L2-664 [post_title] => Roche Oncology: Strategic Interests Presentation [post_excerpt] => Join the Center for Biotechnology for a presentation on Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => roche-oncology-strategic-interests-presentation [to_ping] => [pinged] => [post_modified] => 2019-04-05 19:57:03 [post_modified_gmt] => 2019-04-05 19:57:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3225 [menu_order] => 98 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

BARDA RFI: Next Generation Blood Products

More Information

CEWIT Medical Technologies and Healthcare Innovations Symposium

More Information

Roche Oncology: Strategic Interests Presentation

More Information